Acute and long-term treatment of mania

Dialogues in Clinical Neuroscience

Volumn 10, Issue 2, 2008, Pages 165-179

  Vieta, Eduard ^a   Sanchez Moreno, Jose ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anticonvulsants; Antipsychotics; Bipolar disorder; Clinical trials; Lithium; Mania

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LICARBAZEPINE; LITHIUM; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PHENYTOIN; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE;

ADD ON THERAPY; AGITATION; AKATHISIA; ATAXIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; BLURRED VISION; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONVALESCENCE; DEPRESSION; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; HYPOTHYROIDISM; INCREASED APPETITE; LIVER TOXICITY; LONG TERM CARE; MANIA; MEDICAL DECISION MAKING; MONOTHERAPY; NAUSEA; NERVOUSNESS; OVARY POLYCYSTIC DISEASE; POLYDIPSIA; POLYURIA; PRURITUS; PSYCHOEDUCATION; PSYCHOTHERAPY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM COMPOUNDS; NEUROPHARMACOLOGY; SAFETY; TIME;

EID: 47749115357     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. World Health Organization. The World Health Report 2001;Mental Health: New Understanding. New Understanding, New Hope. Geneva, Switzerland: World Health Organization; 2001.
2. Goodwin FK, Jamison KR. Manic-Depressive Illness. 2nd ed. New York, NY: Oxford University Press; 2007.
3. Martinez-Aran A, Vieta E, Colom F, et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord. 2004;6:224-232.
4. Martinez-Aran A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry. 2004;161:262-270.
5. Vieta E, Rosa AR. Evolving trends in the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2007;8:4-11.
6. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 2005;7(suppl 4):21-33.
7. Berk M, Dodd S. Efficacy of atypical antipsychotics in bipolar disorder. Drugs. 2005;65:257-269.
8. Vieta E, Panicali F, Goetz I, et al. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord. 2008;106:63-72.
9. Fink M. ECT in therapy-resistant mania: does it have a place? Bipolar Disord. 2006;8:307-309.
10. Valenti M, Benabarre A, Garcia-Amador M, et al. Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. Eur Psychiatry. 2008;23:53-56.
11. Vieta E. Bipolar mixed states and their treatment. Expert Rev Neurother. 2005;5:63-68.
12. Vieta E. The treatment of mixed states and the risk of switching to depression. Eur Psychiatry. 2005;20:96-100.
13. Colom F, Vieta E, Daban C, et al. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord. 2006;93:13-17.
14. Vieta E. Managing Bipolar Disorder in Clinical Practice. London, UK: Current Medicine Group Ltd; 2007.
15. Fountoulakis KN, Vieta E, Sanchez-Moreno J, et al. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord. 2005;86:1-10.
16. Bowden CL. Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. J Clin Psychiatry. 1998;59(suppl 6):13-19.
17. Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997;54:37-42.
18. Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry. 1994;164:149-152.
19. Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006;8:625-639.
20. Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006;8:618-624.
21. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66:111-121.
22. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994;271:918-924.
23. Vieta E. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry. 2003;16:23-27.
24. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord. 1980;2:279-288.
25. Johnstone EC, Crow TJ, Frith CD, et al. The Northwick Park "functional" psychosis study: diagnosis and treatment response. Lancet. 1988;2:119-125.
26. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry. 1998;155:12-21.
27. Pope HG, Jr., McElroy SL, Keck PE, Jr, et al. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991;48:62-68.
28. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011-1017.
29. Vieta E. Divalproex versus olanzapine in mania. J Clin Psychiatry. 2003;64:1266-1267.
30. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002;63:1148-1155.
31. Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006;67:1501-1510.
32. Curtis D, Kerr M. NICE recommendations for valproate treatment are unhelpful. Br J Psychiatry. 2005;186:447.
33. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology. 1993;27:138-145.
34. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol. 1978;2:159-175.
35. Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004;65:478-484.
36. Weisler RH, Keck PE, Jr, Swann AC, et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005;66:323-330.
37. Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry. 1987;48:89-93.
38. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry. 1991;48:915-921.
39. Small JG, Klapper MH, Marhenke JD, et al. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull. 1995;31:265-272.
40. Mishory A, Yaroslavsky Y, Bersudsky Y, et al. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry. 2000;157:463-465.
41. Popova E, Leighton C, Bernabarre A, et al. Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Exp Rev Neurother. 2007;7:617-626.
42. Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry. 1967;16:118-126.
43. Prien RF, Caffey EM, Jr., Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry. 1972;26:146-153.
44. Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry. 1975;32:34-42.
45. Cookson J, Silverstone T, Wells B. Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. A test of the dopamine hypothesis. Acta Psychiatr Scand. 1981;64:381-397.
46. Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75-84.
47. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15:573-585.
48. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218-1226.
49. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146-1154.
50. Muller-Oerlinghausen B, Retzow A, Henn FA, et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol. 2000;20:195-203.
51. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187:235-242.
52. Vieta E, Ramey T, Keller D, et al. Ziprasidone in the treatment of acute mania: A 12-week placebo-controlled, haloperidol referenced study. J Psychopharmacol. In press.
53. McElroy SL, Dessain EC, Pope HG, Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 1991;52:411-414.
54. Barbini B, Scherillo P, Benedetti F, et al. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol. 1997;12:109-112.
55. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry. 1996;153:759-764.
56. Hirschfeld RM, Keck PE, Jr., Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057-1065.
57. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:229-234.
58. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182:141-147.
59. Dwight MM, Keck PE, Jr., Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet. 1994;344:554-555.
60. Vieta E, Herraiz M, Parramon G, et al. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord. 2002;72:15-19.
61. Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry. 2001;62:818-825.
62. Vieta E, Herraiz M, Fernandez A, et al. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). J Clin Psychiatry. 2001;62:623-630.
63. Vieta E. Olanzapine in bipolar disorder. Exp Opin Pharmacother. 2004;5:1613-1619.
64. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;156:702-709.
65. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000;57:841-849.
66. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999;14:339-343.
67. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62-69.
68. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163:247-256.
69. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;21:923-934.
70. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004;6:213-223.
71. Yatham LN, Vieta E, Young AH, et al. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol. 2007;22:212-220.
72. Keck PE, Jr., Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748.
73. Potkin SG, Keck PE, Jr., Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25:301-310.
74. Fountoulakis KN, Vieta E, Siamouli M, et al. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry. 2007;6:27.
75. Weisler R, Dunn J, English P. Ziprasidone in adjunctive treatment of acute bipolar mania: randomized, double-blind, placebo-controlled trial. Paper presented at: 16th European College of Neuropsychopharmachology Congress. Prague, Czech Republic; 20-24 September. 2003.
76. Lyseng-Williamson KA, Perry CM. Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs. 2004;18:367-376.
77. Keck PE, Jr., Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
78. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20:536-546.
79. Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to valproate or lithium in bipolar patients with mania who were partially non-reponsive to valproate/lithium: A placebo-controlled study. Am J Psychiatry. 2008. In press.
80. Vieta E, Ros S, Goikolea JM, et al. An open-label study of amisulpride in the treatment of mania. J Clin Psychiatry. 2005;66:575-578.
81. Amann B, Sterr A, Mergl R, et al. Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disord. 2005;7:471-476.
82. McIntyre R, Panagides J, Alphs L, et al. Treatment of mania in bipolar I disorder: a placebo- and olanzapine-controlled trial of asenapine (ARES 7501005). Paper presented at: 20th ECNP Congress. Vienna, Austria; October 13-17, 2007.
83. McIntyre R, Panagides J, Alphs L, et al. Efficacy and tolerability of asenapine and olanzapine in acute mania: A double-blind extension study (ARES 7501006). Paper presented at: 20th ECNP Congress. Vienna, Austria; October 13-17, 2007.
84. Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol. 2007;10:123-129.
85. Colom F, Vieta E. Sudden glory revisited: cognitive contents of hypomania. Psychother Psychosom. 2007;76:278-288.
86. Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. 2001;CD003013.
87. Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand. 1999;100:406-417.
88. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217-222.
89. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
90. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.
91. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290:1467-1473.
92. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord. 1986;10:115-125.
93. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481-489.
94. Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry. 2005;162:2152-2161.
95. Lambert P, Venaud G. Comparative study of valpromide versus lithium in treatment of affective disorders. Nervure. 1992;5:57-65.
96. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160:1263-1271.
97. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology. (Berl) 1981;73:95-96.
98. Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis. Br J Psychiatry. 1995;166:378-381.
99. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord. 1997;43:151-161.
100. Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998;18:455-460.
101. Hartong EG, Moleman P, Hoogduin CA, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry. 2003;64:144-151.
102. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65:432-441.
103. Vieta E. Maintenance therapy for bipolar disorder: current and future management options. Exp Rev Neurother. 2004;4:S35-S42.
104. Mishory A, Winokur M, Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord. 2003;5:464-467.
105. Vieta E, Manuel GJ, Martinez-Aran A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry. 2006;67:473-477.
106. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull. 1993;29:375-381.
107. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 1980;13:156-167.
108. Hummel B, Dittmann S, Forsthoff A, et al. Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders. A case series. Neuropsychobiology. 2002;45(suppl 1):37-42.
109. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry. 1999;156:1164-1169.
110. Brown ES, Thomas NR, Carmody T, et al. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry. 2001;34:80-81.
111. Yatham LN, Binder C, Riccardelli R, et al. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol. 2003;18:227-235.
112. Yatham LN, Binder C, Kusumakar V, et al. Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania. Int Clin Psychopharmacol. 2004;19:103-109.
113. Vieta E, Nieto E, Autet A, et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry. 2008. In press.
114. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162:1281-1290.
115. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337-345.
116. Sajatovic M, Brescan DW, Perez DE, et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry. 2001;62:728-732.
117. Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. In press.
118. Weisler R, Warrington L, Dunn J, et al. Adjunctive ziprasidone in bipolar mania: short and long-term data. Program and abstracts of the American Psychiatric Association, Annual Meeting. New York, NY; May 1-6, 2004.
119. Keck PE, Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626-637.
120. Carta MG, Zairo F, Mellino G, et al. An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients. Clin Pract Epidemol Ment Health. 2006;2:19.
121. Sienaert P, Peuskens J. Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder. Bipolar Disord. 2006;8:304-306.
122. Tsao CI, Jain S, Gibson RH, et al. Maintenance ECT for recurrent medication-refractory mania. J ECT. 2004;20:118-119.
123. Perry A, Tarrier N, Morriss R, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999;318:149-153.
124. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003;60:402-407.
125. Miklowitz DJ, Wisniewski SR, Miyahara S, et al. Perceived criticism from family members as a predictor of the one-year course of bipolar disorder. Psychiatry Res. 2006;144:153-166.
126. Reinares M, Colom F, Sanchez-Moreno J, et al. Impact of caregivers group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord. 2008;10:511-519.
127. Scott J, Paykel E, Morriss R, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry. 2006;188:313-320.
128. Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003;60:145-152.
129. Lam D, Wright K, Smith N. Dysfunctional assumptions in bipolar disorder. J Affect Disord. 2004;79:193-199.
130. Frank E. Interpersonal and social rhythm therapy: a means of improving depression and preventing relapse in bipolar disorder. J Clin Psychol. 2007;63:463-473.
131. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry. 2000;48:593-604.
132. Colom F, Vieta E. Psychoeducation Manual for Bipolar Disorder. Cambridge, UK: Cambridge University Press; 2006.